120 related articles for article (PubMed ID: 9194148)
1. Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex.
Pehek EA; Bi Y
Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):671-82. PubMed ID: 9194148
[TBL] [Abstract][Full Text] [Related]
2. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex.
Pehek EA
Synapse; 1996 Sep; 24(1):12-8. PubMed ID: 9046072
[TBL] [Abstract][Full Text] [Related]
3. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum.
Pehek EA
J Pharmacol Exp Ther; 1999 Apr; 289(1):14-23. PubMed ID: 10086982
[TBL] [Abstract][Full Text] [Related]
5. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
[TBL] [Abstract][Full Text] [Related]
6. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex.
Nomikos GG; Iurlo M; Andersson JL; Kimura K; Svensson TH
Psychopharmacology (Berl); 1994 Jun; 115(1-2):147-56. PubMed ID: 7862887
[TBL] [Abstract][Full Text] [Related]
8. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
Ichikawa J; Meltzer HY
J Pharmacol Exp Ther; 1999 Dec; 291(3):1227-32. PubMed ID: 10565846
[TBL] [Abstract][Full Text] [Related]
9. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.
Schmidt CJ; Fadayel GM
Eur J Pharmacol; 1995 Feb; 273(3):273-9. PubMed ID: 7737334
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.
Pehek EA; Nocjar C; Roth BL; Byrd TA; Mabrouk OS
Neuropsychopharmacology; 2006 Feb; 31(2):265-77. PubMed ID: 15999145
[TBL] [Abstract][Full Text] [Related]
11. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Bonaccorso S; Meltzer HY; Li Z; Dai J; Alboszta AR; Ichikawa J
Neuropsychopharmacology; 2002 Sep; 27(3):430-41. PubMed ID: 12225700
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat.
Nair SG; Gudelsky GA
Brain Res; 2004 Jul; 1013(2):168-73. PubMed ID: 15193525
[TBL] [Abstract][Full Text] [Related]
13. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner.
Liégeois JF; Ichikawa J; Meltzer HY
Brain Res; 2002 Aug; 947(2):157-65. PubMed ID: 12176156
[TBL] [Abstract][Full Text] [Related]
14. 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
Brain Res; 2003 May; 972(1-2):216-21. PubMed ID: 12711095
[TBL] [Abstract][Full Text] [Related]
15. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
Ago Y; Nakamura S; Baba A; Matsuda T
Neuropsychopharmacology; 2005 Jan; 30(1):43-51. PubMed ID: 15383832
[TBL] [Abstract][Full Text] [Related]
16. The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex.
Devoto P; Flore G; Saba P; Bini V; Gessa GL
Addict Biol; 2014 Jul; 19(4):612-22. PubMed ID: 23289939
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
18. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell.
King D; Zigmond MJ; Finlay JM
Neuroscience; 1997 Mar; 77(1):141-53. PubMed ID: 9044382
[TBL] [Abstract][Full Text] [Related]
19. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.
Balla A; Sershen H; Serra M; Koneru R; Javitt DC
Neuropsychopharmacology; 2003 Jan; 28(1):34-44. PubMed ID: 12496938
[TBL] [Abstract][Full Text] [Related]
20. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.
Ruiu S; Marchese G; Saba PL; Gessa GL; Pani L
Mol Psychiatry; 2000 Nov; 5(6):673-7. PubMed ID: 11126398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
